ESTRO 2025 - Abstract Book

S150

Invited Speaker

ESTRO 2025

In conclusion, personalized NMSC treatment strategies hold significant promise in balancing the goal of achieving improved patient survival through optimal local control of the disease and effective systemic therapy while simultaneously improving or maintaining the patient’s quality of life. Larger-scale controlled clinical trials will be essential to refine these approaches and establish standardized protocols to ensure optimal outcomes for individuals affected by the different types of NMSC.

4919

Speaker Abstracts Moving from single cell genomics towards spatial transcriptomics Roderick Beijersbergen Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, Netherlands

Abstract:

From Single-Cell Genomics to Spatial Transcriptomics

In recent years, there has been a growing recognition of the complex and interactive ecosystem in which cancer cells exist within a tissue. The tumor microenvironment plays a crucial role in driving cancer progression, metastasis, and therapy resistance. Additionally, tumor heterogeneity presents a significant challenge, further complicating our ability to understand and predict therapy responses. Advancements in technology now allow for the study of tissues at the single-cell level, providing insights into genomic characteristics, gene and protein expression, and even metabolic activity. In particular, single-cell and spatial transcriptomic technologies have emerged as powerful tools to explore these critical aspects of cancer biology. In this teaching lecture, we will examine the current landscape of single-cell and spatial transcriptomics, highlighting key innovations and novel developments that enhance our ability to study individual cells within their spatial context.

4920

Speaker Abstracts Radiation oncology in the 2030s Michael Baumann Department of Radiooncology/Radiobiology, German Cancer Research Center, Heidelberg, Germany

Abstract:

Precision radiation oncology exploits the capacity of radiotherapy or combined treatments including radiotherapy to eradicate cancer cells, including cancer stem cells, in a spatially targeted way. Both technological advances, including data sciences, as well as biological innovations will continue to drive the evolution of precision radiation oncology. Examples include particle therapy, advanced (bio)image guidance, adaptive interventions based on biological response assessment, and novel biological strategies predicting and counteracting mechanisms of radioresistance. Biomarkers play a key role not only for future strategies of patient selection but also for precise anatomical targeting, radiation dose prescription, and rational use of combined modality treatments. Biomarker driven trials, including trials such as DELPHI and INDIRA in head and neck squamous cell carcinoma, currently test